Model of translational cancer research in multiple myeloma.

about

DNA synthesis inhibitors for the treatment of gastrointestinal cancer.

P2860

Q38254307-0A491B35-982E-4E78-8910-0EC326CF8551

P2860

Model of translational cancer research in multiple myeloma.

Item

http://www.wikidata.org/entity/Q36498784

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Model of translational cancer research in multiple myeloma.

@ast

Model of translational cancer research in multiple myeloma.

@en

type

Item

label

Model of translational cancer research in multiple myeloma.

@ast

Model of translational cancer research in multiple myeloma.

@en

prefLabel

Model of translational cancer research in multiple myeloma.

@ast

Model of translational cancer research in multiple myeloma.

@en

P1476

Model of translational cancer research in multiple myeloma.

@en

P2093

Hiromu Suzuki

http://www.w3.org/2001/XMLSchema#string

Hiroshi Ikeda

http://www.w3.org/2001/XMLSchema#string

Hiroshi Yasui

http://www.w3.org/2001/XMLSchema#string

Kohzoh Imai

http://www.w3.org/2001/XMLSchema#string

Masanori Nojima

http://www.w3.org/2001/XMLSchema#string

Reo Maruyama

http://www.w3.org/2001/XMLSchema#string

Tadao Ishida

http://www.w3.org/2001/XMLSchema#string

Toshiaki Hayashi

http://www.w3.org/2001/XMLSchema#string

Yasuhisa Shinomura

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Hallmarks of Cancer: The Next Generation

Initial genome sequencing and analysis of multiple myeloma

A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

Epigenetic inactivation of CHFR in human tumors

Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms

The cancer genome

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Defining translational research: implications for training.

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

P304

1907-1912

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1111/J.1349-7006.2012.02384.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2012-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2012-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229324662

http://www.w3.org/2001/XMLSchema#string

P698

22809142

http://www.w3.org/2001/XMLSchema#string

P921

multiple myeloma

P932

3533800

http://www.w3.org/2001/XMLSchema#string

Model of translational cancer research in multiple myeloma.

about

P2860

P2860

Model of translational cancer research in multiple myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P5008

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P5008

P577

P5875

P698

P921

P932